Orchid Pharma's Q3 FY 2025-26 Quarterly Results
- 12 Feb 2026
Result Summary
- Orchid Pharma Ltd reported a 4.2% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Dec (Q3 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a decline of 5.7%.
- Its expenses for the quarter were up by 5.0% QoQ and 7.1% YoY.
- The net profit increased 120.5% QoQ and decreased 160.7% YoY.
- The earnings per share (EPS) of Orchid Pharma Ltd declined at 2.49 during Q3 FY 2025-26.
Financial Statments for Q3 FY 2025-26
Total Income | 212.88 | 204.30 | 225.83 | 4.2% | -5.7% |
Total Expenses | 217.91 | 207.63 | 203.38 | 5.0% | 7.1% |
Profit Before Tax | -12.15 | -3.33 | 22.45 | 264.9% | -154.1% |
Tax | 0.00 | 0.00 | 0.00 | - | - |
Profit After Tax | -12.61 | -5.72 | 20.78 | 120.5% | -160.7% |
Earnings Per Share | -2.49 | -1.13 | 4.10 | 120.4% | -160.7% |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Company Overview
Orchid Pharma Ltd is a pharmaceutical company primarily engaged in the development, manufacture, and marketing of active pharmaceutical ingredients (APIs) and finished dosage formulations. The company operates within the pharmaceutical industry, focusing on therapeutic areas like antibiotics, anti-inflammatory, and anti-cancer drugs. Orchid Pharma has been known for its capabilities in research and development, with a diverse product portfolio catering to global markets. Recent developments in the company are not specifically mentioned in the provided data, so any new strategic initiatives or changes in leadership are not available for discussion.
Revenue
In Q3FY26, Orchid Pharma Ltd reported a total income of ₹212.88 crores, reflecting a quarter-over-quarter (QoQ) increase of 4.2% from ₹204.30 crores in Q2FY26. However, when compared to the previous year's corresponding quarter, Q3FY25, where the total income was ₹225.83 crores, there is a year-over-year (YoY) decline of 5.7%. This fluctuation in total income indicates variations in the company's revenue-generating activities over the periods. The factors contributing to this revenue change are not detailed in the data provided.
Profitability
Orchid Pharma Ltd's profitability in Q3FY26 shows a notable decline compared to the previous year. The company reported a profit before tax of -₹12.15 crores, which marks a significant decrease from the profit before tax of ₹22.45 crores in Q3FY25, representing a YoY change of -154.1%. On a QoQ basis, there is a substantial increase in the loss from -₹3.33 crores in Q2FY26 to -₹12.15 crores, an increase of 264.9%. The profit after tax for Q3FY26 is -₹12.61 crores, down from a profit of ₹20.78 crores in Q3FY25, marking a YoY change of -160.7%, and a QoQ increase in loss from -₹5.72 crores in Q2FY26, indicating a 120.5% change. The earnings per share (EPS) also reflect this trend, decreasing from ₹4.10 in Q3FY25 to -₹2.49 in Q3FY26.
Operating Metrics
The total expenses for Orchid Pharma Ltd in Q3FY26 were ₹217.91 crores, which is an increase of 5.0% QoQ from ₹207.63 crores in Q2FY26 and a YoY increase of 7.1% from ₹203.38 crores in Q3FY25. This rise in expenses could be due to various operational costs, although specific details are not provided in the data. The absence of tax expenses in all the reported quarters suggests either operational losses or the utilization of tax benefits, but further information would be required to confirm this. No specific financial ratios or additional operating metrics are provided for further analysis.